linjc16/ctgov huggingface dataset:
Placenta Accreta; Total Lower Uterine Segmentectomy With Cervico-corporeal Anastomosis

Study Overview
=================
Brief Summary
-----------------
To study feasibility and safety of Total lower uterine segmentectomy with cervico-corporeal anastomosis in conservative management of placenta accreta

Detailed Description
-----------------
Placenta accreta represents a real challenge in modern obstetric care as its incidence is increasing in a parallelism with increased CSs rates. Its management represents another challenge and a multidisciplinary team with clear plans and alternative strategies that fulfill different situation and address different patient needs must be clearly settled in every referral center dealing with placenta accreta. Hysterectomy without trials of placental separation seems to be the standard and logical procedure. However hysterectomy needs to be a total or at least including the entire invaded Lower uterine segment. Hysterectomy is associated with significant blood loss, and loss of future fertility. There are several fertility conservation approaches with variable success rates, complications, technical demands and costs. Uterine plication sutures has been reported as successful uterine conservation strategy but subsequent intrauterine adhesions, weak uterine scar and uterine necrosis might culminate in a functionless uterus. The present work describes total lower uterine segmentectomy with cervical-corporeal anastomosis as a relatively less invasive uterine conservation strategy with minimization of blood loss and transfusion needs. Furthermore, total lower uterine segmentectomy with cervico-corporeal anastomosis has the merits of leaving behind a strong scar and a well-functioning uterus.

Official Title
-----------------
Placenta Accreta; Total Lower Uterine Segmentectomy With Cervico-corporeal Anastomosis, a Feasibility Study

Conditions
-----------------
Placenta Accreta

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pregnant women diagnosed with placenta accreta by us and Doppler Accreta invading the entire or most of the lus Women who welling uterine conservation, Planned and elective cs for women diagnosed with accreta, and accepting participation Exclusion Criteria: women who don't accept participation, women who desire hysterectomy. Women who diagnosed with accrete and placenta separated easily women with concomitant pathology and requiring hysterectomy .
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Success of procedure | Success of procedure regarding ability to preserve the uterus and stoppage of bleeding. The bleeding will be evaluated by haemoglobin level preoperative and postoperative. | 1year |
Lycopene Following Aneurysmal Subarachnoid Haemorrhage

Study Overview
=================
Brief Summary
-----------------
In this study the investigators wish to explore the potential neuroprotective effects of acute oral supplementation of lycopene, a natural anti-oxidant derived from tomatoes, on cerebral vasospasm and autoregulation, and examine whether any improvements translate into a reduction of biochemical markers of vascular injury and inflammation a decrease in the prevalence of secondary strokes following subarachnoid haemorrhage.

Official Title
-----------------
Acute Oral Lycopene Therapy on Cerebral Autoregulation and Delayed Ischaemic Deficits Following Aneurysmal Subarachnoid Haemorrhage (LASH): A Randomized Controlled Trial

Conditions
-----------------
Subarachnoid Hemorrhage, Aneurysm

Intervention / Treatment
-----------------
* Drug: Lycopene
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: > 18 years old, Confirmed aneurysmal subarachnoid hemorrhage (aSAH), Time from ictus < 96 hours Exclusion Criteria: Age: < 18 years old, Non-aneurysmal SAH, Time from ictus > 96 hours, Severe carotid atherosclerotic disease (≥70%) High-dose statin therapy (>80 mg/day fluvastatin; >40 mg/day simvastatin; >40 mg/day pravastatin; >10 mg/day atorvastatin; >10 mg/day rosuvastatin 28), Allergy or hypersensitivity to tomatoes and tomato products and history of any other significant atopy/allergy (e.g. soy, whey, lutein, lecithin)

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Active<br> | Drug: Lycopene<br>* 30 mg oral, daily, for 21 days<br>|
| Placebo Comparator: Placebo<br> | Drug: placebo<br>* starch<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of vasospasm | Mean flow velocity in MCA > 120 cm/min; LR > 3 (4 if age < 50 years old) | Daily for 21 days | 
| Duration of impaired autoregulation measured with transcranial Doppler | Transient hyperaemic response test; Mx | Daily for 21 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Level of biochemical markers of vascular injury: LDL, oxy-LDL, CRP, circulating endothelial cells, endothelial progenitor cells |  | Days: 0, 3, 6, 12, 14, 21 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Aneurysmal subarachnoid hemorrhage (aSAH), Cerebral vasospasm, impaired cerebral autoregulation, transient hyperaemic response test, delayed ischaemic neurological deficits
The Primary Care Obesity Network (PCON): Incorporating Principles of Self-regulation of Intake

Study Overview
=================
Brief Summary
-----------------
In response to the high prevalence rates of childhood obesity in central Ohio, the Center for Healthy Weight and Nutrition (CHWN) established the Primary Care Obesity Network (PCON); a partnership between primary care physicians and Nationwide Children's Hospital's Center for Healthy Weight and Nutrition, a tertiary care obesity center, the first of its kind in Ohio. The overall goal of PCON is to bring an effective and user friendly obesity management program to the community physician's office to prevent and treat the growing number of obese children in the setting of the private office. The predominant nutrition messaging approach to tackling childhood obesity has revolved around the food choices and portion sizes. While this is relevant, an area with significant potential for impact for maintaining optimal growth and a healthy weight for young children is addressing feeding behaviors and self-regulation of intake;. - the how of eating. The investigators objective it to investigate whether this self-regulation approach can be employed for an older age group of 6-11 years old.

Official Title
-----------------
The Primary Care Obesity Network (PCON): Incorporating Principles of Self-regulation of Intake

Conditions
-----------------
Self-regulation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Mother of a 6-11 year old child Exclusion Criteria: Unable to speak and read English
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Mothers of 6-11 year olds<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Examining use of disordered self-regulatory feeding behaviors, at survey completion |  | At survey completion, which will occur about 30 minutes after the survey is administered |
Relationship of Glycemic Index Values and Subjects' Body Composition Parameters

Study Overview
=================
Brief Summary
-----------------
Glycemic index concept is widely used to determine impact of a food to blood glucose. Although the previous studies showed that glycemic index did not seem to be related with subject-specific factors, currently several studies found conflicting results on the relationship of subjects' characteristics and glycemic index values. This study aims to determine whether body composition parameters, as subject-specific factor, correlate with glycemic index values.

Detailed Description
-----------------
Glycemic index methods are performed according to Food and Agricultural Organization/WHO recommendations.

Official Title
-----------------
Correlation of Glycemic Index Values and Subjects' Body Composition Parameters

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age between 20-40 years fasting blood glucose 70-100 mg/dL Indonesians Exclusion Criteria: having diabetes smoking if women, pregnant or lactating being allergic to food used in this study having gastrointestinal disturbance in regular medication refusal to sign the consent form

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| healthy without diabetes<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| correlation between glycemic value and body composition | Study the correlation between the glycemic values (produced from comparing area under the curve value after ingestion of glucose standard and after consuming test sample) and subjects' body composition parameters: weight, muscle mass, fat mass, percent body fat, BMI, Waist-hip ratio, visceral fat, and estimated trunk fat. Pearson's r and its significance value (p-value) will be reported. | baseline | 
| glycemic index values of instant noodle | The glycemic index is a calculated from measurements of area under the glucose curve after the food is eaten, divided by the corresponding area after the control food is eaten. The value is multiplied by 100 to represent a percentage of the control food. | 2 hours postprandial glucose | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
glycemic index, body composition
Experimental Study to Validate the Modified Glucose Disposal Test

Study Overview
=================
Brief Summary
-----------------
Evaluate the modified GDT as a measure of key metabolic characteristics in healthy subjects and those with type 2 diabetes mellitus

Official Title
-----------------
Experimental Medicine Study to Validate the Modified Glucose Disposal Test in Healthy Subjects and Subjects With Type 2 Diabetes

Conditions
-----------------
Diabetes

Intervention / Treatment
-----------------
* Procedure: Insulin, glucose and staple isotopes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of Type 2 diabetes Clinically healthy Drug naive or on a stable dose of metformin monotherapy and/or a secretagogue Exclusion Criteria: Type 1 Diabetes History of significant heart disease. Bariatric surgery Exposure to fibrates, thiazolidinediones, insulin, exenatide, pramlintide or DPP-IV inhibitors

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Arm 1<br>Beta cell function by frequently sampled intravenous glucose tolerance test | Procedure: Insulin, glucose and staple isotopes<br> <br> |
| Other: Arm 2<br>Modified glucose disposal test assessment of insulin sensitivity, endogenous glucose production and insulin secretion | Procedure: Insulin, glucose and staple isotopes<br> <br> |
| Other: Arm 3<br>Endogenous glucose production and insulin sensitivity by isotope dilution and isoglycemic, heperinsulinemic clamp | Procedure: Insulin, glucose and staple isotopes<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glucose (labeled and unlabeled), insulin and c-peptide will be measured to calculate insulin sensitivity, endogenous glucose production and insulin secretion |  | within 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Characterize the patterns of intermediate metabolites in healthy subjects and subjects with type 2 diabetes mellitus |  | within 24 hours |
The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization

Study Overview
=================
Brief Summary
-----------------
This study will explore the effect of clopidogrel on coated-platelets in patients who are given a loading dose before diagnostic catheterization or percutaneous coronary intervention. We hypothesis that clopidogrel will reduce the percentage of platelets that are coated and therefore more hypercoagulable.

Detailed Description
-----------------
Platelet activity will be determined by light transmission aggregometry at baseline, after a 300 mg dose of clopidogrel and after the catheterization and/or angioplasty procedure. The change in the percentage of platelets that are coated platelets will be determined.

Official Title
-----------------
The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization

Conditions
-----------------
Coronary Artery Disease, Chest Pain

Intervention / Treatment
-----------------
* Drug: Clopidogrel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients given clopidogrel loading dose before scheduled catheterization or percutaneous intervention Exclusion Criteria: Acute coronary syndrome Unable to tolerate clopidogrel

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Clopidogrel|All subjects will receive a 300 mg loading dose|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Percentage of Coated Platelets After the Administration of Clopidogrel in Patients Undergoing Cardiac Catheterization and/or Angioplasty | The percentage of platelets that are collagen coated after the administration of clopidogrel. | 24 hours after the administration of clopidotrel | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Percentage of Coated Platelets After Coronary Angiography and/or PCI | The percentage of coated platelets 24 hours after coronary angiography and/or PCI | 6 hrs after procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Platelets, platelet aggregation inhibitors
Is the Daytime Sleepiness Based on Epworth Sleepiness Scale a Good Way to Assess Taiwanese With Suspected Obstructive Sleep Apnea.

Study Overview
=================
Brief Summary
-----------------
This observational survey with retrospective follow-up is designed to study the daytime sleepiness based on Epworth Sleepiness Scale a good way or not to assess Taiwanese with suspected obstructive sleep apnea.

Detailed Description
-----------------
Daytime sleepiness (DS) is a complicated clinical problem, often indicating a serious underlying physiological abnormality and associated with higher prevalence of comorbid conditions such as diabetes, myocardial infarction, and stroke. Daytime sleepiness is also the cardinal symptoms of obstructive sleep apnea. How to identify the high risks patients with obstructive sleep apnea for further polysomnography is a difficult problem for doctors in out-patient department. Different methods have been proposed for measuring sleepiness and the Epworth sleepiness scale (ESS) is the measure of sleepiness most commonly used in sleep research and clinical settings. However, whether Epworth sleepiness scale is a good tool with high predictive value of obstructive sleep apnea is not evaluated in the population of Taiwanese. This observational study is set up to document these practices.

Official Title
-----------------
Is the Daytime Sleepiness Based on Epworth Sleepiness Scale a Good Way to Assess Taiwanese With Suspected Obstructive Sleep Apnea.

Conditions
-----------------
Obstructive Sleep Apnea

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with polysomnography during 2016/1/1-2019/12/31 Exclusion Criteria: age under 20 year-old incomplete polysomnography incomplete chart information patients with narcolepsy patients with previous diagnosed with obstructive sleep apnea, including already patients with obstructive sleep apnea under treatment

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between Epworth sleepiness scale and the severity of obstructive sleep apnea | use analysis to calculate the correlation | baseline (The Epworth sleepiness scale was completed just before the polysomnography) | 
| The specificity and sensitivity of Epworth sleepiness scale for obstructive sleep apnea | use receiver operating characteristic curve (cut point of 10) to calculate the specificity and sensitivity | Baseline (The Epworth sleepiness scale was completed just before the polysomnography) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Questionnaire: If there are some specific symptoms as a tool with better sensitivity or specificity than Epworth sleepiness scale for obstructive sleep apnea |  | Baseline |
Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to define the mechanisms that underlie the refractory pruritus (itch) in Cutaneous T-Cell Lymphoma (CTCL).

Detailed Description
-----------------
Little is known about the fundamental cause of pruritus in CTCL, however we do know the malignant CD4+ T-cells of CTCL accumulate in the epidermis and are in close proximity to the neural, immune and vascular systems that influence and regulate the biology of the skin. The close proximity of malignant CD4+ T-cells with the key mediators in the itch process could result in the pruritus experienced by patients with CTCL. To accomplish this we are collecting and examining skin biopsies for CTCL patients and healthy controls to identify itch-associated local biomarkers of the disease. In addition to these skin biopsies, we are retrospectively examining existing paraffin-embedded skin biopsy tissue blocks from CTCL patients. We are performing comparative and quantitative immunohistochemical analyses on the samples. This study will help to determine which components in the skin are potential key players in the manifestation and maintenance of recalcitrant pruritus in patients with CTCL.

Official Title
-----------------
Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma

Conditions
-----------------
Cutaneous T-Cell Lymphoma

Intervention / Treatment
-----------------
* Procedure: skin biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with CTCL Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Skin Biopsy<br> | Procedure: skin biopsy<br>* Lidocaine 1% c Epinephrine for local anesthesia<br>* Other names: Lidocaine;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collection of biopsies from pruritic CTCL patients, non pruritic CTCL patients and controls and analysis of a panel of itch-associated local biomarkers in an attempt to characterize and quantify the components in the skin involved. |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pruritis, itch, CTCL